Boston Scientific Corporation
300 Boston Scientific Way
Tel: (800) 876-9960
1495 articles with Boston Scientific Corporation
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24, 2019 at 8:00 a.m. EDT.
Late-breaking Clinical Trial Highlights Positive Safety and Efficacy Data for the LUMINIZE™ RF Balloon Catheter
New data showcasing performance of recently acquired RF balloon-based, single-shot ablation technology
Boston Scientific Corporation announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association in Lisbon, Portugal, on March 17-19.
VIVA Physicians Selects NAMSA as Statistical Analytic Group to Evaluate the Safety of Paclitaxel Drug-Eluting Technologies in PAD
VIVA Physicians announced the selection of NAMSA as the independent statistical analysis group to examine individual patient-level data associated with paclitaxel-coated balloons and stent trials used in the treatment of peripheral artery disease in the superficial femoral artery.
Boston Scientific Corporation will participate in the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 in Boston.
Boston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes
Boston Scientific Corporation completed a public offering of $4.3 billion aggregate principal amount of its senior notes.
Boston Scientific Corporation announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under the Company's shelf registration statement.
Boston Scientific Corporation (NYSE: BSX) will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 in New York City.
Boston Scientific Corporation generated sales of $2.561 billion during the fourth quarter of 2018.
New Four-Year Data Demonstrate Rezūm™ Water Vapor Therapy Offers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms
Boston Scientific Corporation today announced that data from a randomized clinical trial demonstrate that Rezūm™ Water Vapor Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH), provides durable results and preserves sexual function four years after treatment.
Boston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads
Boston Scientific Corporation (NYSE: BSX) has launched the Vercise™ Primary Cell (PC) and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems featuring the Vercise Cartesia™ Directional Lead
VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages
Results from the VIRTUS Study Show Venous Stent Met Its Primary Effectiveness and Safety Endpoints in Re-establishing Blood Flow at Twelve Months
The Journal of the American Heart Association (JAHA) published an article in December saying that paclitaxel-coated balloons and stents manufactured by Boston Scientific and others had an increased risk of death.
All Patent Litigation Between the Companies to be Dismissed
Boston Scientific Corporation generated sales, based upon preliminary unaudited financial information, of approximately $2.56 billion during the fourth quarter of 2018
Boston Scientific is exercising its option to buy the remaining shares of Santa Rosa, Calif.-based Millipede. The original deal was entered into in January 2018, when Boston Scientific acquired $90 million shares with the option to buy the remaining $325 million, which the company did yesterday.
Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system
Boston Scientific Corporation (NYSE: BSX) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 in San Francisco, California.
Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent
Boston Scientific to Participate in 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference
Boston Scientific will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 in New York City.